Immunocytochemical detection of leukocyte-associated and apoptosis-related antigen expression in childhood brain tumors

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 3-16

  Bodey, Bela ^a   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Active cell death; Apoptotic bodies; Appotosis programmed cell death; Calcium and magnesium dependant endonucleases; Cancer therapy; Childhood astrocytomas

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; ENDONUCLEASE; FAS ANTIGEN; FAS LIGAND; FORMALDEHYDE; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RECEPTOR; STREPTAVIDIN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ASTROCYTOMA; BRAIN TUMOR; CELL LINE; CELL MATURATION; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRANULOCYTE; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MEDULLOBLASTOMA; NATURAL KILLER CELL; NEUROECTODERM TUMOR; PROMYELOCYTE; SCREENING; T LYMPHOCYTE; TECHNIQUE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, SURFACE; APOPTOSIS; BRAIN NEOPLASMS; CHILD; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES;

EID: 0034978245     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00119-6     Document Type: Conference Paper

References (196)

1. Brain tumors: challenges and directions
2. Primary pediatric tumours of the central nervous system. Anatomopathological study of 623 cases
3. Chemotherapy for pediatric brain tumors
4. Primitive neuroectodermal tumors of the central nervous system
5. Primitive neuroepithelial tumors of the central nervous system
6. Embryonal central neuroepithelial tumors: current concepts and future challenges
7. Primitive neuroectodermal tumors
8. Childhood tumors
9. Primary intracranial neoplasms of infancy and early childhood
10. Neurotrophins in cerebellar granule cell development and medulloblastoma
11. Medulloblastoma: survival and late recurrence after the Collins' risk period
12. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization
13. Macroglial cell development in embryonic rat brain: studies using monoclonal antibodies, flourescence-activated cell sorting and cell culture
14. Statistical study of brain tumours in the neurosurgical clinics in Japan
15. Molecular pathways in the formation of gliomas
16. Histopathology, classification, and grading of gliomas
17. The biology of astrocytoma: lessons learned from chronic myelogenous leukemia-hypothesis
18. Membrane phenotypes of human leukemic cells and leukemic cell lines: Clinical correlates and biological implications
19. Molecular genetic markers in lymphoproliferative disorders
20. Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies
21. Genetic alterations associated with the evolution and progression of astrocytic brain tumors
22. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
23. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer
24. Dysgerminoma of the ovary. An immunohistochemical study of tumor-infiltrating lymphoreticular cells and tumor cells
25. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation
26. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles
27. Immunophenotypic characterization of infiltrating poly- and mononuclear cells in childhood brain tumors
28. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells
29. Oligoclonal T cells in human cancer
30. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
31. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors
32. Role of apoptosis in health and disease
33. Cell deaths in normal vertebrate ontogeny
34. Death in embryonic systems
35. Patterns of cell death
36. cdc2 activation required for apoptosis
37. Cell cycle and apoptosis: common pathways to life and death
38. Apoptosis and the cell cycle
39. Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis
40. Life, death, and the pursuit of apoptosis
41. Control of programmed cell death in normal and leukemic cells: new implication for therapy
42. Regulation of apoptosis in immune cells
43. Defining apoptosis
44. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome
45. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics
46. Apoptosis: mechanisms and roles in pathology
47. The role of proteases during apoptosis
48. Dicing with death: dissecting the components of the apoptosis machinery
49. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
50. Cell death: the significance of apoptosis
51. Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis
52. Apoptosis: the role of the endonuclease
53. Endogenous endonuclease induced DNA fragmentation: An early event in cell mediated cytolysis
54. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death
55. Apoptosis and cancer
56. Phagocyte recognition of cells undergoing apoptosis
57. Monoclonal antibody-mediated tumor regression by induction of apoptosis
58. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
59. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas
60. Induction of apoptosis in fibroblasts by c-myc protein
61. Bcl-2: a repressor of lymphocyte death
62. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation
63. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators
64. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo
65. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
66. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions
67. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death
68. Fas and Fas ligand: a death factor and its receptor
69. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody
70. Fas transduces activation signals in normal human T lymphocytes
71. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
72. Lethal effect of the anti-Fas antibody in mice
73. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family
74. Purification and characterization of the Fas ligand that induces apoptosis
75. The Fas death factor
76. The Fas/APO-1 receptor and its deadly ligand
77. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease
78. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
79. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
80. Abnormal thymocyte development and production of autoreactive T cells in TCR transgenic autoimmune mice
81. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mouse
82. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse
83. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement
84. Activation interferes with the APO-1 pathway in mature human T cells
85. Dephosphorylation of a 65kD protein associated with signaling for Fas-mediated apoptosis (Abstract)
86. c-Myc and apoptosis
87. Thymocyte apoptosis induced by p53-dependent and independent pathways
88. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2
89. Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas
90. Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression
91. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance
92. 1
93. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
94. Bcl-2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells
95. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
96. Bcl-2 is the guardian of microtubule integrity
97. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax that accelerates programmed cell death
98. The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death
99. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death
100. Mechanisms and genes of cellular suicide
101. Bcl-2 and the regulation of programmed cell death
102. The overexpression of bcl-2 inhibits UVA-mediated immediate apoptosis in rat 6 fibroblasts: evidence for the involvement of bcl-2 as an antioxidant
103. Human ICE/CED-3 protease nomenclature
104. Induction of apoptosis by the mouse Nedd 2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1β-converting enzyme
105. Ich-1, an ICE/Ced-3 related gene, encodes both positive and negative regulators of programmed cell death
106. Identification and characterization of ICH-2, a novel member of the interleukin-1β-converting enzyme family of cysteine proteases
107. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme
108. Mch2, a new member of the apoptotic Ced-3/ICE cysteine protease gene family
109. relIII members of the ICE/Ced-3 family of cysteine proteases
110. ICE-LAP3, a novel mammalian homologue of of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis
111. ICE-LAP6, a novel member of the ICE-Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B
112. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death
113. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
114. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
115. Apoptosis or planning a death
116. A simplified classification of gliomas
117. Grading of Gliomas
118. Principles of the new World Health Organization (WHO) classification of brain tumors
119. Grading of astrocytomas. A simple and reproducible method
120. Tumors of central neuroepithelial origin
121. Histological typing of tumors of the central nervous system
122. Histologic classification of central nervous system tumors by the World Health Organization
123. Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
124. A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry
125. Improved antigen retrieval in formalin-fixed, paraffin-embedded tissues
126. Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies
127. Antigen retrieval pretreatment: microwaving procedures and alternative heating methods
128. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure
129. Immunoalkaline phosphatase cytochemistry
130. Improved avidin-biotin peroxidase complex (ABC) staining
131. Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry
132. Non-specific binding of mouse myeloma IgM immunoglobulins by human myelin sheetes and astrocytes
133. The avidin-biotin reaction as an universal amplification system in immunoassays
134. Introduction to avidin-biotin technology
135. Prevention of nonspecific binding of avidin
136. The biotin-(strept)avidin system: principles and applications in biotechnology
137. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing
138. The checkerboard tissue block. An improved multitissue control block
139. Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
140. Apoptosis: the physiologic pathway of cell death
141. Expression of APO-1, a cell surface molecule mediating apoptosis, during normal B cell ontogeny and in B cell tumors. Co-expression and coregulation of APO-1 and ICAM-1 (CD54) in germinal central cells
142. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype
143. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
144. Activation interferes with the APO-1 pathway in mature human T cells
145. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia
146. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression
147. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas
148. Programmed cell death, apoptosis and killer genes
149. The role of apoptotic and necrotic processes in cytolysis mediated by LAK cells with different phenotypes
150. Apoptosis in prostate cancer after hormonal treatment
151. APO-1 (CD95) and Bcl-2: determinants of cell death in the human thymus
152. Regulation of apoptosis in the immune system
153. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
154. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis
155. CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases
156. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play
157. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells
158. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells
159. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
160. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells
161. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas
162. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines
163. Immunobiology of gliomas: new perspectives for therapy. In: Holmes F.F., Kepes J.J., Vats T.S., Schuler D., Nyary I., editors. Challenges and opportunities in pediatric oncology
164. Bcl-2 initiates a new category of oncogenes: regulators of cell death
165. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
166. The bcl-2 gene and 14;18 translocation in lymphoproliferative disorders
167. Effect of Bcl-2 on Fas antigen mediated cell death
168. Inactivation of bcl-2 by phosphorylation
169. Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells
170. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 signal transduction pathway
171. Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
172. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
173. Bcl-2 functions in an antioxidant pathway to prevent apoptosis
174. Movement of Bax from the cytosol to mitochondria during apoptosis
175. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations
176. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin
177. In situ T cells in melanoma
178. Tumor progression, early diagnosis and prognosis of melanoma
179. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma
180. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors
181. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer
182. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma
183. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas
184. Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer
185. Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report
186. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells
187. Transforming growth factor-beta: biological function and chemical structure
188. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype
189. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells
190. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction
191. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression